LENZ Therapeutics commercializes VIZZ™ (aceclidine ophthalmologic solution) 1.44%, the first FDA‑approved eye drop that pharmacologically restores near vision for presbyopia. The once‑daily, non‑surgical treatment enhances the eye’s accommodative response, offering eye‑care professionals and pharmacies a drug‑based alternative to reading glasses for adults aged 45 and older.
Funding
$30M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
RCFounders
Product
Problem
Presbyopia, the age‑related loss of near vision, affects over 1.8 billion people worldwide, with 128 million adults in the United States experiencing reduced reading ability and reliance on reading glasses or multifocal lenses.
Solution
Lenz Therapeutics commercializes VIZZ™ (aceclidine ophthalmologic solution) 1.44%, the first FDA‑approved aceclidine‑based eye drop for presbyopia. The once‑daily formulation restores near vision by pharmacologically improving the eye’s accommodative response, offering a non‑surgical, drug‑based alternative to corrective lenses. VIZZ™ is positioned for broad adoption across the adult population aged 45 and older, with distribution in the U.S. and ongoing licensing efforts for international markets. By delivering a pharmaceutical solution that can be administered at home, the company aims to increase accessibility and convenience for patients seeking vision restoration.
Target Audience
Primary customers are eye‑care professionals (ophthalmologists, optometrists) and retail pharmacies that prescribe or dispense vision‑correction products to adults aged 45 and older with presbyopia.
Features
- FDA‑approved 1.44 % aceclidine eye drop specifically indicated for presbyopia treatment
- Once‑daily dosing regimen designed for ease of use without the need for surgical intervention
- Proven pharmacologic mechanism that enhances accommodative amplitude to improve near vision
- Commercial launch in the United States with active licensing partnerships to expand global availability
- Manufactured under GMP‑compliant processes ensuring product quality and regulatory compliance